ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út 29-33. Tel.: +36-1-391-9400 FAX: +36-1-391-9409 Automated TB diagnosis Robot.

Slides:



Advertisements
Similar presentations
TB 101 “Basic Facts on Tuberculosis”
Advertisements

Diagnosis of Smear negative pulmonary TB in high HIV settings: RESEARCH PRIORITIES Haileyesus Getahun, Stop TB, WHO. Expert consultation on TB/HIV research.
ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: The Worlds only known robotic,
ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: The Worlds first robotic, LED.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
PPM-DOTS in Cambodia Working with Private Pharmacies DOTS Expansion WG Meeting Paris 15 th October 2008 Dr. Mao Tan Eang Director National Center for TB.
Improving diagnosis TB laboratory strengthening.
Prize for TB low-cost point of care rapid diagnostic test Pierre Chirac Médecins Sans Frontières, Paris, France Campaign for Access to Essential Medicines.
Breaking Silos: TB and Poverty Bobby Ramakant, Rachael Thomson STOP TB Partnership TB and Poverty Subgroup.
Cambodia Diabetes self-help groups MoPoTsyo Patient Information Centre Maurits van Pelt.
Help For Malaria Erin J. Engelson, University of Washington Michael Sterner, University of Washington Nono Ayivi-Guedehoussou, Harvard University.
Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.
Accelerating PMDT scale up in Ethiopia
Recommendations to Improve Dengue Control in the Philippines
Monitoring and Evaluation: Tuberculosis Control Programs
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
World Health Organization
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
1 TB/HIV Project in the Philippines Yumiko Yanase.
Total health ODA commitments, US$ Billions.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
Partnerships in TB Vaccine Research & Development
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
TB DIAGNOSTICS R&D: Not Just Technology Peter Mehlape, General Manager GBC Southern Africa Conference 11th October 2010, Johannesburg BD Experience with.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
DEPARTMENT OF HEALTH DOTS Program for TB (Tuberculosis Directly Observed Short-course)
Colorado Department of Public Health and Environment Tuberculosis Prevention and Control Program.
Tuberculosis Research of INA-RESPOND on Drug-resistant
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
1 Module OVERVIEW OF EXTERNAL QUALITY ASSESSMENT.
Monitoring Drug Resistant Tuberculosis Treatment in Brazil through an Innovative Web-based Information System Dr. Luis Gustavo Bastos Management Sciences.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
FIND Ongoing Activities What’s in the pipeline for Rapid DST? WHO Stop TB Department Supranational Reference Laboratory Network Meeting Paris, October.
1 FIND and Operational Research in HIV-Associated Tuberculosis Rick O’Brien Foundation for Innovative New Diagnostics, Geneva.
National TB Stakeholders’ meeting How best can TB experts work with the media to inform and engage the communities A journalist’s perspective Catherine.
Dr K N Prasad Community Medicine
1 |1 | Dr Karin Weyer Stop TB Department Geneva, Switzerland Strategic guidance on the use of laboratory technologies DEWG Meeting, Geneva: 13 October.
Japan Dr. Ismail M. Aboshama Zidan Surveillance Coordinator of NTP-Egypt Action Plan to Strengthen Laboratory Diagnostic.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
NATIONAL TB 2012 INDICATOR ANALYSIS REPORT Presented by: Sandile Ginindza Lugogo Sun Hotel 05 th -7 th June 2013 Ministry of Health NTCP.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
PerkinElmer Life Sciences Production Company Meeting - 1st February 2002 Progenesis John Hoyland Product Manager - Bioinformatics.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 8.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
One Healthcare System’s Response to the Chaos Swedish Health Services Swedish Medical Centers: Ballard, Cherry Hill, Edmonds, First Hill, & Issaquah Ambulatory.
PERSPECTIVES FROM THE FIELD DR LYDIA MUNGHERERA TASO (The Aids Support Organisation) UGANDA REVERSING THE TIDE OF TB.
Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.
The role of prevalence surveys in measuring the burden of TB, progress in TB control and improving early case detection Ikushi Onozaki WHO/STB/TBS Global.
GLOBAL TB PROGRAMME Systematic screening for active TB – operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme.
Revolutionizing TB Control with Innovation in New Diagnostics Dr Giorgio Roscigno Chief Executive Officer, FIND Reversing the Tide: the End of Tuberculosis,
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
Global Fund Grant Proposal Round 11: Tuberculosis Nathan Furukawa Gabriella Boyle Rebekah Miner Paa Kobina Forson Xiaoxue Huang Hunter Pugh Gap Analysis.
Gap Analysis: Tuberculosis Care in Malawi Round 11 proposal to the Global Fund to Fight AIDS, Tuberculosis and Malaria Africa 3: Team Malawi Arianna, Babatunde,
Outline of Current Situation Survey on HIV/AIDS (Proposal) Ms. Keiko Dozono Director for AIDS and Emerging Infectious Disease Control Health and Safety.
Leading indicators = Impact CURRENT IMPACT Inputs Activities Outputs
Facts about TB incidence
Tuberculosis in children
NDPHS PHC EG Draft Workshop report, Attachment 3
REIMAGING PHARMACEUTICAL INNOVATION.
PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED
بسم الله الرحمن الرحيم.
Project Name: Country:
Global Health Technology
Presentation transcript:

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Automated TB diagnosis Robot Microscope Project Development Plan and Background ConsultASK Ltd

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Facts about TB incidence With 8.8 Mi new cases annually and almost 2 Mi deaths, TB is still a leading mortality factor Overall, one-third of the world's population is currently infected with the TB bacillus. 10% of people who are infected with TB bacilli (but who are not infected with HIV) become sick or infectious at some time during their life. TB is the leading killer of people with HIV 27 countries account for 85% of MDR-TB cases There is huge need for tools that correspond to the medical need at affordable price (WHO report) Annually over USD 1 Bi wss spent on TB diagnostics in 2009, and the sum is increasing Source WHO Nearly 5,000 people die from TB daily, a curable disease in most cases !!

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Further Facts The most commonly used sputum smear microscopy is more than 100 years old, but is the most affordable for the majority of HBC countries It is also the most ineffective, detects only half of patients tested with currently used manual method, mainly due to low sensitivity, lack of well trained personel, tiring factor. The vast majority of TB patients can be successfully treated with existing drugs, Delay in assessing proper diagnostics costs time, money and leads to continued transmission of infections TB drains 12 billion USD from the annual incomes of the poorest communities Loss of productivity attributable to TB approaches 7% of GDP in some countries Source WHO IT IS NOT AN UNCURABLE DISEASE! There is urgent need for more accurate and rapid diagnostic tests (WHO, FIND)

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: The Shocking Facts about TB

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: TB Burden Source WHO

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Sputum smear diagnosis of TB: Light source microscopy ZN staining The fastest and cheapest available method Good specificity Weak sensitivity Trained staff needed Time consuming,10– 15 min./slide Fluorescence microscopy Increased sensitivity More expensive Faster, less tiresome Maintenance requirements (mercury vapour lamps )

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Current market (WHO) Source WHO

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Current smear market (WHO) Source WHO

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: The Global Revised WHO Plan

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Current smear market Source WHO

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Market cont. Current assumptions: –Number of microscopy centers ~70K (58K public, 12K private) –20% of microscopes should be replaced by LED by 2015 (WHO) –1 smear laboratory/ population should be reached by 2015 (WHO) Source WHO - Potential smear market 200 M tests (WHO)

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Fluorobot: the fully automated solution Based on the traditional smear microscopy principle LED fluorescent technique Fully automated –Input / output and moving of the slides –Image capturing and analysis –Intelligent bacterium recognition algorythms Long walk away time Low cost, robust design suitable for high incidence, high burden countires

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Main Features Illumination system using LED technology, much less sensitive, longer lifetime and cheaper than mercury vapour lamps Robust, cost effective X-Y movement Special, fast focusing system Cost effective, dedicated simplified microscope with only one magnification Special image processing and pattern recognition algorithms used for bacteria identification Walk away system, batch processing of 100 – 250 slides Standardised quality, no tiring effect No trained staff needed

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: Major milestones Feasibility Study in Q Functional Model stage was successfully reached Q Laboratory Sample Stage was reached at Q „Proof Of Principle” study was conducted at German TB Reference Laboratory, WHO Supranational Laboratory at Borstel led by Dr. Rüsch-Gerdes in September 2010, with positive outcome „Letter Of Intent” was signed with FIND (Foundation for Innovative New Diagnostics, Geneva) in November 2010 Financing Partner is searched in, to carry the project through Prototype Development (Q3 2012) and Validation (Q1 2013) Industrialization and Test Production Planned Q GoLive of final product (and disposable) planned Q4 2013

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: The new Laboratory Sample

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: What we propose Finalize potential disposable kit (staining kit, slide, slide holder…) Based on the results decide to continue or abort project Join the actual state of the development project and finance further development to Milestone III.) Continue to MS IV. Continue dedicated disposable development If successful continue with ConsultASK on industrialization of product Consider setting up production in Hungary (or partly or wholly in more cost effective environment if necessary) and supply of disposable, with a 3rd round financing

ConsultASK Management Consulting LLC H-1121 Budapest, Konkoly-Thege M. út Tel.: FAX: The Road behind our development team Core team has more than 15 years experience in medical imaging and robotic microscopy Main project in the early 90s was the Seditron urine sediment analyzer developed and produced for Boehringer Mannheim